Delayed parasite elimination in human infections treated with clindamycin parallels 'delayed death' of Plasmodium falciparum in vitro

International Journal for Parasitology

Volumn 37, Issue 7, 2007, Pages 777-785

  Burkhardt, Dominik ^a   Wiesner, Jochen ^b   Stoesser, Nicole ^c,d   Ramharter, Michael ^a,c   Uhlemann, Anne Catrin ^d   Issifou, Saadou ^a,c   Jomaa, Hassan ^b   Krishna, Sanjeev ^d   Kremsner, Peter G ^a,c   Borrmann, Steffen ^e,f  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c ALBERT SCHWEITZER HOSPITAL   (Gabon)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

Apicoplast; Chemosensitivity; Chemotherapy; Clindamycin; Malaria; Plasmodium falciparum

Indexed keywords

CHLOROQUINE; CLINDAMYCIN; FOSMIDOMYCIN; HISTIDINE RICH PROTEIN 2; PROTOZOAL PROTEIN; UNCLASSIFIED DRUG;

ANTIBIOTICS; CHEMOTHERAPY; MALARIA; PARASITE; PARASITE INFESTATION;

ADULT; ANTIMALARIAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DEATH; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MAJOR CLINICAL STUDY; MALARIA; MONOTHERAPY; NONHUMAN; PARASITE DEVELOPMENT; PARASITEMIA; PLASMODIUM FALCIPARUM; SCHOOL CHILD; SIMULATION;

ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIGENS, PROTOZOAN; CLINDAMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INHIBITORY CONCENTRATION 50; MALARIA, FALCIPARUM; PARASITEMIA; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; REGRESSION ANALYSIS;

PLASMODIUM FALCIPARUM;

EID: 34247511910     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpara.2006.12.010     Document Type: Article

References (33)

1. Borrmann S., Adegnika A.A., Matsiegui P.B., Issifou S., Schindler A., Mawili-Mboumba D.P., Baranek T., Wiesner J., Jomaa H., and Kremsner P.G. Fosmidomycin-clindamycin for Plasmodium falciparum infections in african children. J. Infect. Dis. 189 (2004) 901-908
2. Borrmann S., Issifou S., Esser G., Adegnika A.A., Ramharter M., Matsiegui P.B., Oyakhirome S., Mawili-Mboumba D.P., Missinou M.A., Kun J.F., Jomaa H., and Kremsner P.G. Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. J. Infect. Dis. 190 (2004) 1534-1540
3. Camps M., Arrizabalaga G., and Boothroyd J. An rRNA mutation identifies the apicoplast as the target for clindamycin in Toxoplasma gondii. Mol. Microbiol. 43 (2002) 1309-1318
4. Carryn S., Chanteux H., Seral C., Mingeot-Leclercq M.P., Van Bambeke F., and Tulkens P.M. Intracellular pharmacodynamics of antibiotics. Infect. Dis. Clin. North Am. 17 (2003) 615-634
5. Fichera M.E., Bhopale M.K., and Roos D.S. In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob. Agents Chemother. 39 (1995) 1530-1537
6. Fichera M.E., and Roos D.S. A plastid organelle as a drug target in apicomplexan parasites. Nature 390 (1997) 407-409
7. Geary T.G., and Jensen J.B. Effects of antibiotics on Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 32 (1983) 221-225
8. Hand W.L., and King-Thompson N.L. Membrane transport of clindamycin in alveolar macrophages. Antimicrob. Agents Chemother. 21 (1982) 241-247
9. He C.Y., Shaw M.K., Pletcher C.H., Striepen B., Tilney L.G., and Roos D.S. A plastid segregation defect in the protozoan parasite Toxoplasma gondii. EMBO J. 20 (2001) 330-339
10. Kremsner P.G., Zotter G.M., Feldmeier H., Graninger W., Westerman R.L., and Rocha R.M. Clindamycin treatment of falciparum malaria in Brazil. J. Antimicrob. Chemother. 23 (1989) 275-281
11. Kremsner P.G., Winkler S., Brandts C., Neifer S., Bienzle U., and Graninger W. Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon. J. Infect. Dis. 169 (1994) 467-470
12. Kremsner P.G., Radloff P., Metzger W., Wildling E., Mordmuller B., Philipps J., Jenne L., Nkeyi M., Prada J., Bienzle U., et al. Quinine plus clindamycin improves chemotherapy of severe malaria in children. Antimicrob. Agents Chemother. 39 (1995) 1603-1605
13. Kremsner P.G., and Krishna S. Antimalarial combinations. Lancet. 364 (2004) 285-294
14. Krudsood S., Silachamroon U., Wilairatana P., Singhasivanon P., Phumratanaprapin W., Chalermrut K., Phophak N., and Popa C. A randomized clinical trial of combinations of artesunate and azithromycin for treatment of uncomplicated Plasmodium falciparum malaria in Thailand. Southeast Asian J. Trop. Med. Public Health 31 (2000) 801-807
15. Lambros C., and Vanderberg J.P. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65 (1979) 418-420
16. Lell B., and Kremsner P.G. Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob. Agents Chemother. 46 (2002) 2315-2320
17. Mazur D., Schug B.S., Evers G., Larsimont V., Fieger-Buschges H., Gimbel W., Keilbach-Bermann A., and Blume H.H. Bioavailability and selected pharmacokinetic parameters of clindamycin hydrochloride after administration of a new 600 mg tablet formulation. Int. J. Clin. Pharmacol. Ther. 37 (1999) 386-392
18. McGready R., Cho T., Samuel, Villegas L., Brockman A., van Vugt M., Looareesuwan S., White N.J., and Nosten F. Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. Trans. R. Soc. Trop. Med. Hyg. 95 (2001) 651-656
19. Noedl H., Wernsdorfer W.H., Miller R.S., and Wongsrichanalai C. Histidine-rich protein II: a novel approach to malaria drug sensitivity testing. Antimicrob. Agents Chemother. 46 (2002) 1658-1664
20. Noedl H., Wongsrichanalai C., Miller R.S., Myint K.S., Looareesuwan S., Sukthana Y., Wongchotigul V., Kollaritsch H., Wiedermann G., and Wernsdorfer W.H. Plasmodium falciparum: effect of anti-malarial drugs on the production and secretion characteristics of histidine-rich protein II. Exp. Parasitol. 102 (2002) 157-163
21. Pfefferkorn E.R., and Borotz S.E. Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin. Antimicrob. Agents Chemother. 38 (1994) 31-37
22. Pukrittayakamee S., Imwong M., Looareesuwan S., and White N.J. Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Trop. 89 (2004) 351-356
23. Ramya T.N., Mishra S., Karmodiya K., Surolia N., and Surolia A. Inhibitors of non-housekeeping functions of the apicoplast defy 'delayed death' in Plasmodium falciparum. Antimicrob. Agents Chemother. 51 (2006) 307-316
24. Roos D.S. The apicoplast as a potential therapeutic target in Toxoplasma and other apicomplexan parasites: some additional thoughts. Parasitol. Today 15 (1999) 41
25. Seaberg L.S., Parquette A.R., Gluzman I.Y., Phillips Jr. G.W., Brodasky T.F., and Krogstad D.J. Clindamycin activity against chloroquine-resistant Plasmodium falciparum. J. Infect. Dis. 150 (1984) 904-911
26. Sidhu A.B., Sun Q., Nkrumah L.J., Dunne M.W., Sacchettini J.C., and Fidock D.A. In vitro efficacy, resistance selection and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. J. Biol. Chem. (2006) (E pub ahead of print)
27. Sullivan M., Li J., Kumar S., Rogers M.J., and McCutchan T.F. Effects of interruption of apicoplast function on malaria infection, development, and transmission. Mol. Biochem. Parasitol. 109 (2000) 17-23
28. Trager W., and Jensen J.B. Human malaria parasites in continuous culture. Science 193 (1976) 673-675
29. White N.J., and Krishna S. Treatment of malaria: some considerations and limitations of the current methods of assessment. Trans. R. Soc. Trop. Med. Hyg. 83 (1989) 767-777
30. White N.J. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob. Agents Chemother. 41 (1997) 1413-1422
31. White N.J. Antimalarial drug resistance. J. Clin. Invest. 113 (2004) 1084-1092
32. WHO, 2002. Sources and prices of selected drugs and diagnostics for people living with HIV/AIDS. In, WHO/EDM/PAR/2002.2.
33. Wiesner J., and Seeber F. The plastid-derived organelle of protozoan human parasites as a target of established and emerging drugs. Expert Opin. Ther. Targets 9 (2005) 23-44